PPGN Share Price Performance
CHF 0
-22.50 (-100.00%)
Price CHF 0
Fair ValueCHF 38.45
Share Pricen/a
Narrative Update • Jul 10
PolyPeptide Group AG Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
PPGN Community Narratives
AN
Fair Value
·Fair Value CHF 38.45 13.9% overvalued intrinsic discount
Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
PK
Fair Value
·Fair Value CHF 33.1 32.3% overvalued intrinsic discount
Biotech longerterm bet
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value CHF 25.77 70.0% overvalued intrinsic discount
Metabolic Capacity Expansion And Peptide Outsourcing Shifts Will Face Headwinds Yet Ultimately Support Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Metabolic Capacity Expansion And Peptide Outsourcing Shifts Will Face Headwinds Yet Ultimately Support Upside
PolyPeptide is riding the wave of booming demand for new peptide medicines, but its big capacity build-out and growing focus on obesity drugs could backfire if projects slip, prices soften, or factories sit idle. See why some analysts think expectations have run ahead of what the business can realistically deliver in the next few years.Read more
AN
CHF 25.77
70.0% overvalued intrinsic discount
Fair Value
Profit Margin
12.07%
Future PE
12.87x
Price in 2029
CHF 29.65
Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity
PolyPeptide Group is rapidly shifting toward making peptides used in new weight-loss and diabetes medicines, and it’s building new manufacturing capacity to meet what it sees as long-lasting demand. The big question is whether customers fill that new capacity fast enough—and keep choosing Western suppliers—so profits can finally improve instead of getting squeezed by delays and competition.Read more
AN
CHF 38.45
13.9% overvalued intrinsic discount
Fair Value
Profit Margin
11.41%
Future PE
21.03x
Price in 2029
CHF 44.27
Metabolic Peptide Demand And New Capacity Will Support Stronger Long Term Earnings Potential
Catalysts About PolyPeptide Group PolyPeptide Group is a contract development and manufacturing partner focused on therapeutic peptides, serving pharmaceutical and biotechnology customers across development and commercial stages. What are the underlying business or industry changes driving this perspective?Read more
AN
CHF 43.88
0.2% undervalued intrinsic discount
Fair Value
Profit Margin
11.75%
Future PE
23.1x
Price in 2029
CHF 50.56
Trending Discussion
No trending discussion available.
Recently Updated Narratives
PK
Biotech longerterm bet
Fair Value: CHF 33.1 32.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PPGN: Takeover Hopes Will Test Sustainability Of Recent Share Price Surge
Fair Value: CHF 25.77 70.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PPGN: Raised Price Views Will Likely Overstate Takeover Hopes
Fair Value: CHF 38.45 13.9% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
PolyPeptide Group AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 13, 2026
- -0.64
- 16.77%
- -5.44%
- 35.3%
About PPGN
- Founded
- 1952
- Employees
- 1440
- CEO
- WebsiteView website
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
